Pain free efficacy of sumatriptan in the early treatment of migraine

Canadian Journal of Neurological Sciences

Volumn 33, Issue 1, 2006, Pages 73-79

  Jelinski, Susan E ^a   Becker, Werner J ^a,e   Christie, Suzanne N ^b   Ahmad, Faiz F ^c   Pryse Phillips, William ^c,d   Simpson, Scott D ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Ottawa Headache Centre   (Canada)

^c GLAXOSMITHKLINE   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 33645330956     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710000473X     Document Type: Article

References (28)

1. O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol. 1994; 23:1020-6.
2. Gibbs TS, Fleischer AB, Jr., Feldman SR, et al. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache. 2003; 43:330-5.
3. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002; 58:885-94.
4. Gerth WC, Carides GW, Dasbach EJ, et al. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics. 2001; 19:197-206.
5. Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia. 1999; 19:50-7.
6. Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology. 1998; 50:1741-5.
7. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991; 325:316-21.
8. Visser WH, Ferrari MD, Bayliss EM, et al. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. Cephalalgia. 1992; 12:308-13.
9. Nappi G, Sicuteri F, Byrne M, et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994; 241:138-44.
10. Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. 1995; 45:S5-9.
11. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. 1995; 45:S10-14.
12. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998; 79:964-82.
13. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther. 2000; 22:1035-48.
14. Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003; 78:1214-22.
15. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004; 24:925-33.
16. Klapper J, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004; 24:918-24.
17. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache. 2004; 44:669-73.
18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8 Suppl 7:1-96.
19. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003; 12:963-74.
20. Goadsby PJ. Serotonin 5-HT receptor agonists in migraine. CNS Drugs. 1998; 10:271-86.
21. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358:1668-75.
22. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001; 89:107-10.
23. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004; 55:19-26.
24. Sramek JJ, Hussey EK, Blements B, Cutler NR. Oral sumatriptan pharmacokinetics in the migraine state. Clin Drug Invest. 1999; 17:137-44.
25. Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003; 102:835-42.
26. Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res. 2001; 4:105-25.
27. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999; 19:484-94.
28. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 Suppl 1:9-160.